Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma.
Gamble LD, Purgato S, Henderson MJ, Di Giacomo S, Russell AJ, Pigini P, Murray J, Valli E, Milazzo G, Giorgi FM, Cowley M, Ashton LJ, Bhalshankar J, Schleiermacher G, Rihani A, Van Maerken T, Vandesompele J, Speleman F, Versteeg R, Koster J, Eggert A, Noguera R, Stallings RL, Tonini GP, Fong K, Vaksman Z, Diskin SJ, Maris JM, London WB, Marshall GM, Ziegler DS, Hogarty MD, Perini G, Norris MD, Haber M. Gamble LD, et al. Among authors: van maerken t. Cancers (Basel). 2021 Apr 9;13(8):1807. doi: 10.3390/cancers13081807. Cancers (Basel). 2021. PMID: 33918978 Free PMC article.
Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.
Van Maerken T, Speleman F, Vermeulen J, Lambertz I, De Clercq S, De Smet E, Yigit N, Coppens V, Philippé J, De Paepe A, Marine JC, Vandesompele J. Van Maerken T, et al. Cancer Res. 2006 Oct 1;66(19):9646-55. doi: 10.1158/0008-5472.CAN-06-0792. Cancer Res. 2006. PMID: 17018622
Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L, Rihani A, Michaelis M, Cinatl J Jr, Cuvelier CA, Marine JC, De Paepe A, Bracke M, Speleman F, Vandesompele J. Van Maerken T, et al. J Natl Cancer Inst. 2009 Nov 18;101(22):1562-74. doi: 10.1093/jnci/djp355. Epub 2009 Nov 10. J Natl Cancer Inst. 2009. PMID: 19903807
An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours.
Mestdagh P, Fredlund E, Pattyn F, Rihani A, Van Maerken T, Vermeulen J, Kumps C, Menten B, De Preter K, Schramm A, Schulte J, Noguera R, Schleiermacher G, Janoueix-Lerosey I, Laureys G, Powel R, Nittner D, Marine JC, Ringnér M, Speleman F, Vandesompele J. Mestdagh P, et al. Among authors: van maerken t. Oncogene. 2010 Jun 17;29(24):3583-92. doi: 10.1038/onc.2010.106. Epub 2010 Apr 12. Oncogene. 2010. PMID: 20383195
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, De Paepe A, Laureys G, Schulte JH, Schramm A, Van Den Broecke C, Vermeulen J, Van Roy N, Beiske K, Renard M, Noguera R, Delattre O, Janoueix-Lerosey I, Kogner P, Martinsson T, Nakagawara A, Ohira M, Caron H, Eggert A, Cools J, Versteeg R, Speleman F. De Brouwer S, et al. Among authors: van maerken t, van roy n, van den broecke c. Clin Cancer Res. 2010 Sep 1;16(17):4353-62. doi: 10.1158/1078-0432.CCR-09-2660. Epub 2010 Aug 18. Clin Cancer Res. 2010. PMID: 20719933
57 results